Researchers evaluated the global rates of incidence, prevalence, and disability-adjusted life years of migraine from 1990 to 2021.
Galcanezumab provided greater reductions in migraine frequency, resulting in a shift from chronic to episodic migraine over a 12-month period compared with placebo.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback